mRNA Technologies: Vaccines vs Therapeutics

Messenger RNA (mRNA) technology surged into the global spotlight during the COVID-19 pandemic, showcasing its power to rapidly deliver effective vaccines. But the potential of mRNA goes far beyond preventing infectious diseases. Today, this transformative platform is also shaping the future of personalized medicine, opening new possibilities in oncology, rare genetic disorders, and beyond.

Though mRNA vaccines and mRNA therapeutics stem from the same foundational science, their applications diverge significantly. At Curapath, we recognize that moving an mRNA product from concept to clinic requires more than innovative science, it demands scalable, flexible, and regulatory-compliant manufacturing tailored to the unique demands of each use case.

Let’s explore how these two paths, vaccines and therapeutics, start from a common core, yet branch out with distinct goals, development challenges, and manufacturing strategies.

1. What do all mRNA-based products have in common? 

Whether used to prevent disease or to treat it, all mRNA-based products share a common scientific backbone. Regardless of their final application, these molecules are typically built around four key pillars:

• In vitro transcription (IVT): This enzymatic process synthesizes mRNA from a DNA template, enabling precise control over sequence and structure.

• Nucleoside modifications: Chemical modifications, such as pseudouridine or N1-methylpseudouridine, are often incorporated to increase mRNA stability, enhance protein translation, and reduce innate immune activation.

• Purification: Sophisticated purification techniques remove impurities, including double-stranded RNA (dsRNA), which can trigger strong immune responses and compromise efficacy.

• Delivery systems: mRNA is inherently unstable and vulnerable to degradation, requiring encapsulation for protection and effective cellular uptake. Lipid nanoparticles (LNPs) and Viral Vector like AAV or LVV are the most widely used and clinically validated delivery platform, particularly for hepatic delivery. However, other vectors are gaining traction, including polymer-based nanoparticles, lipid–polymer hybrids, exosomes, and peptide-based carriers. These alternatives aim to improve targeting, reduce toxicity, and expand the range of tissues and indications that can be addressed.

2. How do mRNA vaccines and mRNA therapeutics differ?

The key distinction lies in their purpose.

mRNA vaccines are designed to prevent disease. Rather than introducing an antigen directly, they deliver genetic instructions that enable the body’s own cells to produce it. This triggers an immune response and establishes immunological memory. Their adaptability makes them particularly powerful against emerging pathogens.

mRNA therapeutics, in contrast, are developed to treat existing conditions. These products can instruct cells to produce therapeutic proteins, compensate for genetic deficiencies, or modulate immune responses.

Current clinical applications extend beyond infectious disease and include personalized cancer vaccines, protein replacement strategies for rare genetic disorders, and in vivo gene editing approaches delivering molecular tools such as CRISPR systems.

Applications range from enzyme replacement in rare diseases to immune activation in cancer. Unlike vaccines, these therapies often require repeated dosing, tight control over protein expression, and targeted delivery to specific tissues or cell types.

How do these differences shape development strategies? 

The intended use of the product fundamentally defines how it is developed.

Vaccines are typically designed for large populations, which requires highly standardized, scalable, and reproducible processes. Speed, manufacturing capacity, and global distribution, often under strict cold chain requirements, are critical success factors.

The global rollout of mRNA vaccines during the COVID-19 pandemic demonstrated the scalability of this platform, with billions of doses produced and distributed in record time.

Therapeutics operate in a very different space. Many applications, particularly in oncology, are moving toward personalization. For example, cancer vaccines can be tailored to a patient’s specific tumor neoantigens, introducing a level of complexity that standard platforms are not designed to handle.

This shift brings new challenges, including smaller batch sizes, increased variability, and the need for enhanced traceability and regulatory oversight. 

Comparative Overview

5. What are the main manufacturing challenges for mRNA products? 

Although vaccines and therapeutics follow the same high-level manufacturing workflow, IVT, purification, formulation, and fill-finish, the complexity within each step can differ significantly depending on the application.

In IVT, achieving precise nucleotide ratios and consistent enzymatic performance is essential to ensure reproducible product quality. During purification, removing immunostimulatory impurities becomes particularly critical, especially at large scale.

Formulation introduces another layer of control. Encapsulation into LNPs must be performed under tightly regulated conditions, often using microfluidic technologies to ensure particle uniformity, encapsulation efficiency, and batch-to-batch consistency.

Where the divergence becomes most evident is in operational requirements. Vaccines benefit from high-throughput, automated systems. Therapeutics, especially personalized ones, demand flexible manufacturing platforms capable of adapting to patient-specific needs and rapid turnaround times.

The manufacturing strategy is critical to succes because the same scientific platform does not translate into a single manufacturing model.

Applying a large-scale, standardized approach to personalized therapeutics can create inefficiencies and compromise quality. Conversely, overly complex processes can hinder the scalability required for vaccines.

Success in mRNA development depends not only on the molecule itself, but on the ability to align manufacturing with the product’s intended use, balancing scalability, flexibility, and regulatory compliance.

6. Where is the field of mRNA heading? 

mRNA is redefining both public health and precision medicine, expanding beyond vaccines into areas like oncology, rare diseases, and protein replacement. The next phase of innovation will not be driven only by new biology, but by the ability to deliver, manufacture, and scale these therapies effectively.

This includes improving delivery technologies to enhance stability, reduce toxicity, and enable more precise tissue targeting. A key challenge is expanding delivery beyond the liver to reach organs such as the lungs and tumors, which remain difficult with current systems.

At the same time, manufacturing must evolve to support both large-scale vaccine production and flexible, rapid platforms for personalized treatments. Advances in process development and scalable infrastructure will be critical to enable this shift.

At Curapath, we specialize in translating breakthrough ideas into real-world treatments. With a foundation built on regulatory excellence, state-of-the-art infrastructure, and expert process development, we’re ready to help you bring your mRNA product to life.

Are you ready to scale up your mRNA product? Partner with Curapath to take the next step with confidence.

Voice of the experts 

“The platform flexibility and shared mechanisms of mRNA technologies are unwavering constants in a rapidly evolving landscape. However, upscaling and GMP-manufacturing demand distinct approaches. mRNA vaccines aim for high-output, standardized production, whereas therapeutics face the intricacies of custom development and individualized treatments.”

Juan José Arroyo, Head of Project Management office at Curapath